Balance Sheet

v3.10.0.1
Consolidated Balance Sheets - USD ($)
Jun. 30, 2018
Dec. 31, 2017
Current Assets    
Cash and cash equivalents $ 24,660,733 $ 9,763,067
Accounts receivable 14,253 14,833
Prepaid expenses and other current assets 4,007,815 1,967,257
Total Current Assets 28,682,801 11,745,157
Property and Equipment, net 645,734 286,891
Other Assets    
Restricted cash 1,170 2,292
In-process R&D 5,866,000 5,866,000
Goodwill 2,189,338 2,189,338
Deposits 79,220 69,798
Deferred financing costs 30,000
Total Other Assets 8,135,728 8,157,428
Total Assets 37,464,263 20,189,476
Current Liabilities    
Accounts payable 821,822 1,033,680
Deferred revenue 5,130,684 7,026,388
Accrued expenses and other liabilities 1,445,867 2,276,431
Total Current Liabilities 7,398,373 10,336,499
Long Term Liabilities    
Other long term liabilities 156,141 160,559
Deferred tax liability 1,302,220 1,302,220
Contingent consideration 3,160,387 2,609,289
Total Liabilities 12,017,121 14,408,567
Commitments and Contingencies
Stockholders' Equity    
Common stock, $.0002 par value; 100,000,000 shares authorized, 23,093,584 and 4,200,310 shares issued and outstanding at June 30, 2018 (unaudited) and December 31, 2017, respectively 4,619 840
Additional paid-in capital 103,953,477 76,382,262
Accumulated deficit (76,423,163) (68,846,326)
Accumulated other comprehensive loss (94,754) (166,025)
Total Stockholders' Equity-Heat Biologics, Inc. 27,440,179 7,370,751
Non-Controlling Interest (1,993,037) (1,589,842)
Total Stockholders' Equity 25,447,142 5,780,909
Total Liabilities and Stockholders' Equity $ 37,464,263 $ 20,189,476

Source